These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 29249180)

  • 1. The effects of transdermal rotigotine on non-motor symptoms of Parkinson's disease: a multicentre, observational, retrospective, post-marketing study.
    Valldeoriola F; Salvador A; Gómez-Arguelles JM; Marey J; Moya M; Ayuga Á; Ramírez F
    Int J Neurosci; 2018 Apr; 128(4):369-375. PubMed ID: 29249180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER.
    Ray Chaudhuri K; Martinez-Martin P; Antonini A; Brown RG; Friedman JH; Onofrj M; Surmann E; Ghys L; Trenkwalder C
    Parkinsonism Relat Disord; 2013 Jul; 19(7):660-5. PubMed ID: 23557594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.
    Hauser RA; Slawek J; Barone P; Dohin E; Surmann E; Asgharnejad M; Bauer L
    BMC Neurol; 2016 Jun; 16():90. PubMed ID: 27267880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
    Kim JM; Chung SJ; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
    BMC Neurol; 2015 Feb; 15():17. PubMed ID: 25879416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial.
    Antonini A; Bauer L; Dohin E; Oertel WH; Rascol O; Reichmann H; Schmid M; Singh P; Tolosa E; Chaudhuri KR
    Eur J Neurol; 2015 Oct; 22(10):1400-7. PubMed ID: 26095948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease.
    Chung SJ; Asgharnejad M; Bauer L; Ramirez F; Jeon B
    Expert Opin Pharmacother; 2016 Aug; 17(11):1453-61. PubMed ID: 27322571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease.
    Giladi N; Fichtner A; Poewe W; Boroojerdi B
    J Neural Transm (Vienna); 2010 Dec; 117(12):1395-9. PubMed ID: 21080009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Night-time use of rotigotine in advanced Parkinson's disease.
    Canesi M; Mariani CB; Isaias IU; Pezzoli G
    Funct Neurol; 2010; 25(4):201-4. PubMed ID: 21388580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders.
    Antonini A; Bernardi L; Calandrella D; Mancini F; Plebani M
    Funct Neurol; 2010; 25(1):21-5. PubMed ID: 20626993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rotigotine for nocturnal hypokinesia in Parkinson's disease: Quantitative analysis of efficacy from a randomized, placebo-controlled trial using an axial inertial sensor.
    Bhidayasiri R; Sringean J; Chaiwong S; Anan C; Penkeaw N; Leaknok A; Boonpang K; Saksornchai K; Rattanachaisit W; Thanawattano C; Jagota P
    Parkinsonism Relat Disord; 2017 Nov; 44():124-128. PubMed ID: 28818560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients' perception of Parkinson's disease-associated pain following initiation of rotigotine: a multicenter non-interventional study.
    Timmermann L; Oehlwein C; Ransmayr G; Fröhlich H; Will E; Schroeder H; Lauterbach T; Bauer L; Kassubek J
    Postgrad Med; 2017 Jan; 129(1):46-54. PubMed ID: 27883297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study.
    Sieb JP; Themann P; Warnecke T; Lauterbach T; Berkels R; Grieger F; Lorenzl S
    Curr Med Res Opin; 2015 May; 31(5):967-74. PubMed ID: 25772231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.
    Sanford M; Scott LJ
    CNS Drugs; 2011 Aug; 25(8):699-719. PubMed ID: 21790211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
    Ceballos-Baumann A; Häck HJ
    Curr Med Res Opin; 2011 Oct; 27(10):1899-905. PubMed ID: 21867400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial.
    Poewe WH; Rascol O; Quinn N; Tolosa E; Oertel WH; Martignoni E; Rupp M; Boroojerdi B;
    Lancet Neurol; 2007 Jun; 6(6):513-20. PubMed ID: 17509486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease.
    Lyons KE; Pahwa R
    Neurol Clin; 2013 Aug; 31(3 Suppl):S51-9. PubMed ID: 23931954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER).
    Trenkwalder C; Kies B; Rudzinska M; Fine J; Nikl J; Honczarenko K; Dioszeghy P; Hill D; Anderson T; Myllyla V; Kassubek J; Steiger M; Zucconi M; Tolosa E; Poewe W; Surmann E; Whitesides J; Boroojerdi B; Chaudhuri KR;
    Mov Disord; 2011 Jan; 26(1):90-9. PubMed ID: 21322021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson's disease.
    Lau YH; Leta V; Rukavina K; Parry M; Ann Natividad J; Metta V; Chung-Faye G; Chaudhuri KR
    J Neural Transm (Vienna); 2022 Jul; 129(7):889-894. PubMed ID: 35503480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.